Biblio
Export 1068 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is T [Clear All Filters]
“Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Post-Translational Chemical Modifications of Amyloid-β Peptides by 4-Hydroxy-2-Nonenal.”, J Alzheimers Dis, vol. 92, no. 2, pp. 499-511, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “Urinary Amino Acid-Conjugated Acrolein and Taurine as New Biomarkers for Detection of Dementia.”, J Alzheimers Dis, vol. 92, no. 1, pp. 361-369, 2023.
, “Alzheimer's Disease Diagnostics Using miRNA Biomarkers and Machine Learning.”, J Alzheimers Dis, vol. 86, no. 2, pp. 841-859, 2022.
, “Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 88, no. 3, pp. 903-931, 2022.
, “Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 86, no. 1, pp. 53-65, 2022.
, “Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 2, pp. 743-752, 2022.
, “Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid-β Burden.”, J Alzheimers Dis, vol. 89, no. 1, pp. 223-232, 2022.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1603-1609, 2022.
,